Meloxicam is a nonsteroidal, anti-inflammatory molecule developed with Axsome’s Molecular Solubility Enhanced Inclusion ...
Patrick Trucchio, an analyst from H.C. Wainwright, reiterated the Buy rating on Mind Medicine (MNMD – Research Report). The associated price ...
Mind Medicine (MindMed) has dosed the first subject in the Phase III Panorama study of a proprietary form of lysergide ...
HonorHealth announced the creation of its new international Center for Translational Science. Sanofi said it will repurchase $5.2 billion of stock and grow profits faster this year as the drugmaker ...
Axsome Therapeutics, Inc. , a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, will host a virtual investor event and conference call today at ...
Selvaraju highlighted Axsome earlier in the week as a Top Pick within their coverage universe, reiterating the Buy rating and emphasizing the company's strengthened position following the FDA's green ...
BuzzFeed on MSN15h
After The Fall Of Roe V Wade, We Asked Men If They'd Be Willing To Take Male Birth Control And Here's What They SaidFollowing the Supreme Court’s overturning Roe v. Wade, conversations about male hormonal birth control have never been more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback